(3R,4S,5S,6R)-4-azido-6-(hydroxymethyl)oxane-2,3,4,5-tetrol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S,5S,6R)-4-azido-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
• 化学式: C6H11N3O6
• 分子量: 221.17
• InChiKey: HSZMAGWEZVZCNR-NURPGYHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  125
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2016113335A1

  公开（公告）日：2016-07-21

  The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一种通式（1）的化合物。通式（1）的化合物适用于治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。此外，本发明涉及一种治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。
• [EN] NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS<br/>[FR] NOUVEAUX INHIBITEURS DE GALECTINES CONTENANT 3-TRIAZOLYL-GALACTOSIDE
  申请人：FORSKAPATENT I SYD AB

  公开号：WO2005113569A1

  公开（公告）日：2005-12-01

  The present invention relates to novel 3-triazolyl-galactosides, the use of said triazolyl-galactosides as medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. Said galactin is preferably a galactin-3.

  本发明涉及新型3-三唑基半乳糖苷，以及将该三唑基半乳糖苷用作药物以及制造用于治疗哺乳动物中与半乳糖结合到受体相关的疾病的药物。所述的半乳糖最好是半乳糖-3。
• NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS
  申请人：Leffler Hakon

  公开号：US20070185041A1

  公开（公告）日：2007-08-09

  The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.

  本发明涉及新型化合物，以及将该化合物用作药物以及制造用于治疗哺乳动物中与galectin与受体结合相关的疾病的药物。所述的galectin通常是galectin-3。
• Novel 3-triazolyl-galactoside inhibitors of galectins
  申请人：Galecto Biotech AB

  公开号：EP2805961A1

  公开（公告）日：2014-11-26

  The present invention relates to a compound of the general formula (I). The compound of formula (I) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及通式（I）的化合物。式（I）化合物适用于治疗哺乳动物（如人类）中与半凝集素（如半凝集素-3）与配体结合有关的紊乱的方法。此外，本发明还涉及一种治疗哺乳动物（如人类）中与半凝集素（如半凝集素-3）与配体结合有关的紊乱的方法。
• Galactoside inhibitor of galectins
  申请人：Galecto Biotech AB

  公开号：US10464964B2

  公开（公告）日：2019-11-05

  An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明的一个实施方案涉及通式化合物。通式化合物适用于治疗哺乳动物（如人类）中与加连蛋白（如加连蛋白-3）与配体结合有关的紊乱的方法。此外，本发明的一个实施方案涉及一种治疗哺乳动物（如人类）中与半凝集素（如半凝集素-3）与配体结合有关的紊乱的方法。